Zusammenfassung
Der 60-jährige Patient wurde am 31.12.2002 wegen schwerer, nicht blutiger Durchfälle, Nachtschweiß, Müdigkeit und subfebrilen Temperaturen sowie allgemeiner Abgeschlagenheit und brennenden perianalen Schmerzen aufgenommen.
Chapter PDF
Similar content being viewed by others
Literatur
Mellors JW, Munoz A, Giorgi JI, et al.: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine 1997; 126: 946–54.
Cameron DW, Heath-Chiozzi M, Danner S, et al.: Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998; 351: 543–9.
Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725–33.
Palella FJ, Jr., Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853–60.
Lee LM, Karon JM, Selik R, etal.: Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984–1997. JAMA 2001; 285: 1308–1315.
Raboud JM, Montaner JS, Conway B, et al.: Suppression of plasma viral load below 20 copies/ml is required to achieve a longterm response to therapy. AIDS 1998; 12: p1619–24.
Kempf DJ, Rode RA, Xu Y, et al.: The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12: F9 - F14.
Hirsch MS, Conway B, D’Aquila RT, et al.: Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society — USA Panel. JAMA 1998; 279:p 1984–91.
Arminio Monforte A, Testa L, Adorni F, et al.: Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages ofHIV-1 infection. AIDS 1998; 12: 1631–7.
Volberding PA, Lagakos SW, Koch MA, et al.: Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med 1990; 322: p941–9.
Mulder JW, Cooper DA, Mathiesen L, et al.: Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk ofprogression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017). AIDS 1994; 8: 313–21.
Volberding PA, Lagakos SW, Grimes JM, et al.: A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med 1995; 333: 401–7.
Concorde Coordinating Committee: Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet 1994; 343: 871–81.
Kinloch-De Loes S, Hirschei BJ, Hoen B, et al.: A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995; 333: 408–13.
Lindbäck S, Vizzard J, Cooper DA, Gaines H: Long-term prognosis following Zidovudine monotherapy in primary human immunodeficiency virus type 1 infection. JID 1999; 179: 1549–52.
Murphy RL, Brun S, Hicks C, et al.: ABT378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS, 2001. 15: p. F1–9.
Rockstroh JK, Bergmann P Wesel W Rieke A, Thiesen A, Fatkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H.: Efficacy and safety of twice daily first-line ritonavir/ indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group. AIDS 2000; 14 (9): 1181–5
Staszewski S, Morales-Ramirez J, Tashima KT, et al.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341: 1865–1873
Staszewski S, Keiser P, Gathe J, etal.: Comparison of antiviral response with abacavir/ combivir to indinavir/combivir in therapy-naive adults at 48 weeks (CNA3005). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, 1999. (Abstract 505).
Ruane P Parenti D, Hessenthaler S, Shepp D, Spragion D, Kauf T, Yau L, St. Clair M, Goodwin D, Hernandez J for the COL30336 Study Team: The PI-sparing, compact, quad regimen of Combivir/Abacavir/efavirenz (AOM/ABC/EFV) is potent and well tolerated in naive subjects with high viral loads: 24-week data. 1st IAS Conference on HIV Pathogenesis and Treatment, BuenosAires, Argentina, July 8–11, 2001, Abstract # 221.
Back DJ, Gibbons SE, Khoo SH, Merry C, Barry MG, Mulcahy FM., Therapeutic drug monitoring of antiretrovirals: ready for the clinic? J Int Assoc Physicians AIDS Care 2000; 6: 34–7.
Piscitelli S, Bechtel C, Sadler B, Falloon J., The addition of a second protease inhibitor eliminated amprenavir-efavirenz interactions and increased amprenavir concentrations. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2000. (Abstract 90).
Saah AJ, Wìnchell G, SeniukM, Deutsch P Multiple-dose pharmacokinetics and tolerability of indinavir-ritonavir combinations in healthy volunteers. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, 1999. (Abstract 136).
Cameron DW, Japour AJ, Xu Y, et al.: Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS, 1999. 13: p. 213–224.
Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243: 1731–1734.
D’Aquila RT, Johnson VA, Welles SL, et al.: Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995; 122: 401–408.
DeGruttola V, Dix L, A ‘Aquila R, et al.: The relationship between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy 2000; 5: 43–50.
Durant.I, Clevenbergh F, Halton F, et al.: Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353: 2195–2199.
Baxter JD, Mayers DL, Wentworth DN, et al.: A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beim Community Programs for Clinical Research on AIDS. AIDS 2000; 14 (9): F83–93.
Cingolani A, Antinori A, Rizzo MG, et al.: Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16: 369–379.
Tural C, Ruiz L, Holtzer C, et al.: Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16: 209–218.
Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AR, Graham NM; VIRA3001 Study Team. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16: 579–88
Meynard JL, Vray M, Morand-Joubert L, et al.: Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: a randomized trial (NARVAL, ANRS 088). Antiviral Therapy 2000;5 suppl 3: 67–68.
The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGuidelines Group for HIV resistance. AIDS 2001; 15: 309–320.
Carpenter CC, Cooper DA, Fischi MA, et al.: Antiretroviral therapy in adults: updated recommendations ofthe International AIDS Society-USA Panel. JAMA 2000; 283: 381–390.
Duwe S, Brunn M, Altmann D, et al.: Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr 2001; 26: 266–273.
Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999; 19: 708–712.
Burger DM, Hoetelmans RMW, Mulder JW, et al.: Low plasma levels of indinavir (IDV) are highly predictive of virological treatment failure in patients using IDV-containing triple therapy. 12th WorldAIDS Conference, Geneva, June 28-July 3, 1998: Abstr. 828
Acosta EP. The promise of therapeutic drug monitoring in HIV infection. August 1999. (http: //www. me d s c ap e.com/medsc ape/ HIV/journal/l999/v05.n04/mha0803/ mha0803. aco s/mha0803 acos-01. html) (See NAPS document no. 05584 for 5 pages, c/o Microfiche Publications, 248 Hempstead Tpke., West Hempstead, NY 11552.)
PiscitelIi SC. The limited value oftherapeutic drug monitoring in HIV infection. August 1999. (http://www.medscape.com/medscape/ HIV/journal/1999/v05.n04/mha0803/ mha0803.pisc/mha0803.pisc-01.html.) (See NAPS document no. 05584 for pages, do Microfiche Publications, 248 Hempstead Tpke., West Hempstead, NY 11552.)
Niehues T, Wintergerst U, Funk M, Notheis G et al.: Empfehlungen zur antiretroviralen Therapie bei HIV-infizierten Kindern. Monatsschr Kinderheilkd 2001; 149: 1372–82.
Deutsch-Österreichische Empfehlungen zur HIV-Therapie in der Schwangerschaft. Aktualisierung Mai 2001. http://www.rki.de/INFEKT/AIDS_STD/ BR_LINIE/BR_LINIE.HTM
Postexpositionelle Prophylaxe nach HIV-Exposition. Deutsch-Österreichische Empfehlungen. Aktualisierung Mai 2002. http://www.rki.de/INFEKT/AIDS_STD/ EXPO/HIV.HTM
Boehm MF, Zhang L, Zhi L, et al. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 1995; 38: 3146–3155
Chambon P. The molecular and genetic dissection of the retinoid signalling pathway. Rec Prog Horm Res 1995; 50: 317–332
Drug Information for the Health Care Professional, USP DI (2002, 22nd Edition, Micromedex-Thompson Healthcare): pp 639–643
Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456–2471
Miller VA, Benedetti FM, Rigas JR, et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997; 15: 790–795
Mukherjee R, Davies PJA, Crombie DL, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997; 386: 407–410
Petkovich M, Brand NJ, KrustA, Chambon P. A human retinoic receptor which belongs to the family of nuclear receptors. Nature 1987; 330: 444–448
Rizvi NA, Marshall JL, Dahut W, et al. A phase I study of LGD 1069 in adults with advanced cancer. Clin Can Res 1999; 5: 1658–1664
Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Eng J Med 1999; 340: 1075–1079
Zackheim HS. Treatment of cutaneous T cell lymphoma with retinoids. Dermatologic Therapy 1998; 13: 207–215
Althaus IW, Chou JJ, Gonzales AJ, et al. Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E. Biochem Pharmacol 1994; 47: 2017–28
Dueweke TJ, Poppe SM, Romero DL et al. U-90153S, a potent inhibitor of human deficiency virus type 1 replication. Antimicrob Agents Chemother 1993; 37: 1127–31
Freimuth WW. Delavirdinemesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. In: Mills J et al. (Eds) Antiviral Chemotherapy 4, Plenum Press, New York 1996, pp 279–289
Lacy CF, Armstrong LL, Goldman MP, Lance LL (Eds) The Drug Information Pocket 2002–2003, Lexi-Comp, Inc —AphA, p. 324
Romero DL. Delavirdine mesylate–antiviral HIV-1 reverse transcriptase inhibitor. Drugs of the Future 1994; 19 (3): 238–242
Scott LJ, Perry CM. Delavirdine: a review of its use in HIV infection. Drugs 2000; 60: 1411–1444
Drug tnformationfor the Health CareProfessional, USP DI (2002, 22nd Edition, Micromedex-Thompson Healthcare): pp 2649–2652
Lea AP, Faulds D. Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs 1996; 51: 846–864
Lin PP Samanta H, Rose RE, etal. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994; 170: 1157–1164
Murray HW, Squires KE, Weiss Wet al. Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089. J Infect Dis 1995; 171 (Suppl 2): S123–130
Petersen EA, Ramirez Ronda CH, Hardy WD et al. Dose related activity of stavudine in patients infected with human immunodeficiency virus. J Infect Dis 1995; 171 (Suppl2): S131 - S139
Rana KZ, Dudley MN. Clinical pharmacokinetics of stavudine Clin Pharmacokinet 1997; 33: 276–284
Richman D, Staszewski S. HIV drug resistence and its implications for antiretroviral treatment strategies. International Medical Press Ltd (2“a Edition), London, Atlanta, 2000:
Skowron G. Biologic effects and safety of stavudine: overview of phase I and II clinical trials. J Infect Dis 1995; 171 (Suppl 2): S113 - S117
Broder S. Pharmacodynamics of2,3’-dideoxycytidine: an inhibitor ofhuman immunodeficiency virus.AmJMed 1990; 88 (Suppl 5B): 2S - 7S
Collier AC, Coombs RW, Schoenfeld DA, et al. Extended treatment with saquinavir (SAQ), zidovudine (ZDV), and zalcitabine (ddC) vs SAQ and ZDV vs ddC and ZDV. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco 1995, Abstract 1173
Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283–291
Devineni D, Gallo JM. Zalcitabine: clinical pharmacokinetics and efficacy. Clin Pharmacokinet 1995; 28: 351–360
Drug Information for the Health Care Professional, USP DI (2002, 22nd Edition, Micromedex-Thompson Healthcare): pp 2963–2966
Fischl MA, Olson RM, Follansbee SE, et al. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who receivedprevious zidovudine therapy. Ann Intern Med 1993; 118: 762–769
Jeffries DJ. The antiviral activityofdideoxycytidine. J Antimicrob Chemother 1989; 23 (Suppl A): 29–34
Meng T-C, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection: a phase VII study. Ann Intern Med 1992; 116: 13–20
Richman D, Staszewski S. HIV drug resistence and its implications for antiretroviral treatment strategies. International Medical Press Ltd ( 2nd Edition ), London, Atlanta, 2000: p. 20–21
Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection ofhuman immunodeficiency virus type 1 resistant to 3 ’ -thiacytidine inhibitors due to a mutation in the YMDDregionofreversetranscriptase. Proc Natl Acad Sci USA 1993; 90: 5653–5656
Whittington R. Brogden RN. Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). Drugs 1992; 44: 656–683
Yarchoan R, Perno CF, Thomas RK et al. Phase I studies of2’,3’-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT) Lancet 1988; 1: 76–81
Alkhatib, G. et al.: CC-CKR5: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272, 1955–1958 (1996).
Amara, A. et al.: HIV coreceptor downregulation as antiviral principle: SDF-la-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV-replication. Journal of Experimental Medicine 186 (1), 139–146 (1997).
Anderson, R.M. et al.: The Spread of HIV-1 in Africa: Sexual Contact Patterns and the Predicted Demographic Impact of AIDS. Nature 352, 581–588 (1991).
Carr, A. et al.: Pathogenesis of HIV-1-Protease Inhibitor-associated peripheral Lipodystrophy, Hyperlipidaemia, and Insulin Resistance. The Lancet 351 (9119), 1881–1883 (1998)
Chantapong, W. et al.: Determination of HIV-1 Subtypes in Injecting Drug Users in Bangkog, Thailand Using Peptide Binding Enzyme Immunoassay and The Heteroduplex Mobility Assay: Evidence of Increasing Prevalence of HIV-1 Subtype E. AIDS 9, 843–849 (1995).
Dietrich, U. et al.: A Highly Divergent HIV-2Related Isolate. Nature 11, 1155–1156 (1989).
Dietrich, U. et al.: HIV-1 Strains from India are Highly Divergent from Prototypic African and US/European Strains, but are Linked to a SouthAfrican Isolate. AIDS 7, 23–27 (1993).
Eigen, M.: Viral Quasispecies. Scientific American 269 (1), 42–49 (1993).
Feng, Y. et al.: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane domain, G-protein coupled receptor. Science 272, 872–877 (1996).
Gao, F. etal.: Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397, 436–441 (1999).
Goulder, P.J.R. and Walker, B.D.: HIV-1 Super-infection–A Word of Caution. New England Journal of Medicine 347 (10), 756–758 (2002).
Grez, M. etal.: Genetic analysis of HIV-1/HIV-2 mixed infections in India reveals a recent spread of HIV-1 and HIV-2 from a single ancestor for each of these viruses. Journal of Virology, 2161–2168 (1994).
Hirsch, M.S. and Curran, J.: Human Immunodeficiency Viruses. Biology and Medical Aspects in Virology edited by Fields, B.N. et al., 1545–1571 (1990).
Levy, J.A.: HIV and The Pathogenesis ofAIDS. 2nd ed. Washington, D.C.: ASM Press, c1998, ISBN: 1–55581–122–1 (1998).
Liu, R. et al.: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multi-exposed individuals to HIV-1 infection. Cell 86, 367–377 (1996).
Mori, K. et al.: Suppression of acute viremia by short term postexposure prophylaxix of SHIV-RT infected monkeys with a novel RT inhibitor (GW420867) allows for development of potent antiviral immune responses. Resulting in efficient containment of infection. Journal of Virology 74, 5747–5753 (2000).
Mosca, J.D. et al.: Herpes simplex virus type 1 can reactivate transcription of latent human immunodeficiency virus. Nature 325, 67–70 (1987).
Oxenius, A. et al.: Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8’ and CD4’ T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 97 (7) 3382–3387 (2000).
Pan, L. et al.: Detection of lasma Viremia in Human Immunodeficiency Virus.Infected Individuals at All Clinical Stages. Journal of Clinical Microbiology 31, 283–288 (1993).
Pedersen C. et al.: The Effect of Treatment with Zidovudine +/- Acyclovir on HIV p24 Antigènaemia in Patients with AIDS or AIDS Related Complex. AIDS 6, 821–825 (1992).
Perelson, A.S. et al.: HIV-1 dynamics in vivo: Clearance rate, infected cell lifespan, and viral generation time. Science 271, 15821586 (1996).
Rosenberg, E.S. etal.: Vigorous HIV-1-specific CD4+T cell responses associated with control of viremia. Science 278, 1447–1450 (1997).
Rübsamen-Waigmann, H. et al.: Reversal of HIV-Phenotype to Fulminat Replication on Macrophages in Perinatal Transmission. The Lancet 11, 1155–1156 (1989).
Rübsamen-Waigmann, H. and Dietrich, U.: Die Ahnen desAIDS-Virus. Bild der Wissenschaft 3, 92–96 (1991).
Rübsamen-Waigmann, H. and Maniar, J.K.: HIV-2 Detected in India. The Microbiologist 2 (1), 4 (1991).
Rübsamen-Waigmann, H.: Spread of HIV-2 in India. The Lancet 337 (3), 550–551 (1991).
Rübsamen-Waigmann, H. et al.: Markers for HIV-Disease Progression in Untreated Patients and Patients Receiving AZT: Evaluation of Viral Activity, AZT, Resistance, Serum Cholesterol b2-Microglobulin, CD4’ Cell Counts, and HIV-Antigen. Infection 19, 219222 (1991).
Rübsamen-Waigmann, H. et al.: High Proportion of HIV-2 and HIV-1/-2 Double-reactive Sera in Two Indian States, Maharashtra and Goa: First Appearance of an HIV-2 Epidemic along with an HIV-1 Epidemic Outside of Africa. Zentralbl. f. Bakteriologie, Mikrobiologie und Hygiene 280, 398–402 (1994).
Rübsamen-Waigmann, H. et al.: HIV-Infektion durch Gerinnungspräparate bei operiertem Patienten. Munch. med. Wschr., 136 (1994).
Rübsamen-Waigmann, H. et al.: Second Generation Non-Nucleosidic Reverse Transcrip-tase Inhibitor HBY 097 and HIV-1 Viral Load. Research Letters Lancet 394, 1517 (1997).
Rübsamen-Waigmann, H.: Neue Konzepte zur Behandlung von AIDS und der HIV-Infektion. Spektrum der Wissenschaft. Dossier: Seuchen, 94–99 (1997).
Rübsamen-Waigmann, H. et al.: Spread of HIV-2 in India. The Lancet 337 (3), 550–551 (1991).
Vesanen, M. et al.: Human Immunodeficiency Virus Type 1 mRNA Splicing Pattern in Infected Persons is Determined by The Proportion of Newly Infected Cells. Virology Vol. 236, 104–109 (1997).
Von Briesen, H. et al.: Isolation Frequency and Growth Properties of HIV-Variants: Multiple Simultaneous Variants in a Patient Demonstrated by Molecular Cloning. J. Med. Virol. 23, 51–66 (1987).
Von Briesen, H. et al.: Systematic Classification of HIV Biological Subtypes on Lymphocytes and Monocytes/Macrophages. Virology 178, 597–602 (1990).
Von Briesen, H. et al.: Infection of Monocytes/ Macrophages by HIV in Vitro. Res. Virol. 141, 251–257 (1990).
Dalichau G.: Gesundheitstrukturgesetz,Kommentar, Loseblattsammlung in 3 Bänden, Verlag RS Schulz GmbH, Starnberg
Dalichau G, Grüner B, Müller-Alten L.: Pflegeversicherung Sozialgesetzbuch (SGB) Elftes Buch (XI) Kommentar sowie Bundes-, Europa-und Landesrecht Losteblattsammlung in 3 Bänden, Verlag RS Schulz GmbH, Starnberg
Dalichau G., Grüner B.: Gesetzliche Krankenversicherung, Sozialgesetzbuch (SGB) Fünftes Buch (V) Kommentar, Loseblattsammlung in 3 Bänden, Verlag RS Schulz GmbH, Starnberg
Exner-Freisfeld H: Soziale Absicherung bei HIV undAIDS, 2. aktualisierte und ergänzte Auflage, VAS Verlag fir akademische Schriften Frankfurt, 2001
Exner-Freisfeld H.: Informationen zu AIDS in der Arbeitswelt, AIDS-Aufklärung e.V. Frankfurt a. Main 2. Auflage erscheint 2004
Fritze E.: Die ärztliche Begutachtung 6. Auf- lage, Steinkopff-Verlag Darmstadt 2001
Gostomzyk JG.: Angewandte Sozialmedizin, Handbuch für Weiterbildung und Praxis Grundwerk 2000, Landsberg/Lech: ecomed
Grigoleit H., Schliehe F., Wenig M.: Handbuch Rehabilitation und Vorsorge Loseblattwerk Asgard Verlag Dr. Werner Hippe GmbH; Sankt Augustin
Grüner B., Dalichau G.: Gesetzliche Rentenversicherung, Sozialgesetzbuch (SGB) Sechstes Buch (VI), Kommentar, Loseblattwerk in 3 Bänden, Verlag RS Schulz GmbH, Starnberg
Jarke J.: AIDS amArbeitsplatz: Berufskrankheit HIV/AIDS in AIDS Herausforderungen für Forschung, Behandlung und das Leben mit HIV AIDS-Monographien, Band 8 2000 verlag moderne industrie-mi, Landsberg/Lech 433–435
Jürgens A., Niermann T: Handbuch der Pflegeeinrichtungen in 2 Bänden Verlag RS Schulz GmbH, Starnberg
Knittel SGB IX-Rehabilitation und Teilhabe Behinderter Menschen Kommentar und Rechtssammlung in 2 Bänden Verlag RS Schulz GmbH, Starnberg
Kruse J., Reinhard HJ.: WinklerJBundessozialhilfegesetz ( BSHG) mitAsylbewerberleistungsgesetz Verlag C.H. Beck München 2002
Leitfaden der Sozialhilfe von A-Z. Ausgabe 2002/2004 AG TuWas, DVS Frankfurt am Main 2002
VDR Sozialmedizinische Begutachtung in der gesetzlichen Rentenversicherung, H. Exner-Freisfeld, S.375ff »HIV-Infektion und AIDS-Erkrankung« Gustav Fischer Verlag 1995
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Helm, E.B. et al. (2003). Sektion II Praxis. In: L’age-Stehr, J., Helm, E.B., Nolde, L. (eds) AIDS und die Vorstadien. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-26741-7_1
Download citation
DOI: https://doi.org/10.1007/978-3-662-26741-7_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-40686-0
Online ISBN: 978-3-662-26741-7
eBook Packages: Springer Book Archive